Author
Dimitrios T. Trafalis
Other affiliations: University of Patras, Health Science University
Bio: Dimitrios T. Trafalis is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 16, co-authored 88 publications receiving 1354 citations. Previous affiliations of Dimitrios T. Trafalis include University of Patras & Health Science University.
Topics: Cancer, Medicine, In vivo, Chemistry, Breast cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: Up-to-date information on MGs treatment including current approaches, novel drug-delivering strategies, molecular targeted agents and immunomodulative treatments are reviewed, and future treatment perspectives are discussed.
550 citations
TL;DR: This article provides a comprehensive review of the early and late phase trials that led to the regulatory approval of all five PD1‐ PDL‐1 inhibitors in the corresponding cancer types and presents available data on the combinations of PD1 • PDL •1 inhibitors with other therapies, the toxicity profile of the PD1• PDL•1 inhibitors and ongoing trials testing the efficacy of these agents in cancer types beyond those that have been addressed already.
220 citations
TL;DR: The results reinforce previous findings about the beneficial action of saffron against Alzheimer's disease and may be of value for the development of novel therapeutic agents based on carotenoid-based dual binding inhibitors.
Abstract: Inhibitors of acetylcholine breakdown by acetylcholinesterase (AChE) constitute the main therapeutic modality for Alzheimer's disease. In the search for natural products with inhibitory action on AChE, this study investigated the activity of saffron extract and its constituents by in vitro enzymatic and molecular docking studies. Saffron has been used in traditional medicine against Alzheimer's disease. Saffron extract showed moderate AChE inhibitory activity (up to 30%), but IC(50) values of crocetin, dimethylcrocetin, and safranal were 96.33, 107.1, and 21.09 μM, respectively. Kinetic analysis showed mixed-type inhibition, which was verified by in silico docking studies. Safranal interacts only with the binding site of the AChE, but crocetin and dimethylcrocetin bind simultaneously to the catalytic and peripheral anionic sites. These results reinforce previous findings about the beneficial action of saffron against Alzheimer's disease and may be of value for the development of novel therapeutic agents based on carotenoid-based dual binding inhibitors.
131 citations
TL;DR: No statistically significant difference in median overall survival in patients with advanced colorectal cancer treated with bevacizumab plus a combination therapy (arm A) and those treated with the combination only, without bevazquezumab (arm B), was observed.
Abstract: Objective: The objective of this phase III trial was to compare chemotherapy combined with bevacizumab versus chemotherapy alone in the treatment of patients with advanced colorecta
102 citations
TL;DR: A number of studies suggest that ITCs can cause cell cycle growth arrest and also induce apoptosis in human malignant melanoma cells, and could serve as promising chemo-therapeutic agents that could be used in the clinical setting to potentiate the efficacy of existing therapies.
Abstract: Many studies have shown evidence in support of the beneficial effects of phytochemicals in preventing chronic diseases, including cancer. Among such phytochemicals, sulphur-containing compounds (e.g., isothiocyanates (ITCs)) have raised scientific interest by exerting unique chemo-preventive properties against cancer pathogenesis. ITCs are the major biologically active compounds capable of mediating the anticancer effect of cruciferous vegetables. Recently, many studies have shown that a higher intake of cruciferous vegetables is associated with reduced risk of developing various forms of cancers primarily due to a plurality of effects, including (i) metabolic activation and detoxification, (ii) inflammation, (iii) angiogenesis, (iv) metastasis and (v) regulation of the epigenetic machinery. In the context of human malignant melanoma, a number of studies suggest that ITCs can cause cell cycle growth arrest and also induce apoptosis in human malignant melanoma cells. On such basis, ITCs could serve as promising chemo-therapeutic agents that could be used in the clinical setting to potentiate the efficacy of existing therapies.
75 citations
Cited by
More filters
01 Jan 2000
3,536 citations
TL;DR: Recent progress on drug metabolism activity profiles, interindividual variability and regulation of expression, and the functional and clinical impact of genetic variation in drug metabolizing P450s are reviewed.
2,832 citations
Journal Article•
2,777 citations
01 Jan 2010
935 citations
TL;DR: Despite aggressive resection and combined modality adjuvant treatment, most GBMs recur and innovative treatments, such as TTFields, drugs to target molecular receptors, and immunotherapy, are promising new options.
Abstract: Background
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. Current treatment options at diagnosis are multimodal and include surgical resection, radiation, and chemotherapy. Significant advances in the understanding of the molecular pathology of GBM and associated cell signaling pathways have opened opportunities for new therapies for recurrent and newly diagnosed disease. Innovative treatments, such as tumor-treating fields (TTFields) and immunotherapy, give hope for enhanced survival.
735 citations